Creative Commons source reading · Alzheimer’s disease and related dementias
Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound.
Nir Lipsman; Ying Meng; Allison J Bethune; Yuexi Huang; Benjamin Lam; Mario Masellis; Nathan Herrmann; Chinthaka Heyn; Isabelle Aubert; Alexandre Boutet; Gwenn S Smith; Kullervo Hynynen; Sandra E Black
Originally published in Nature communications · 2018-07-25
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Magnetic resonance-guided focused ultrasound in combination with intravenously injected microbubbles has been shown to transiently open the blood-brain barrier, and reduce beta-amyloid and tau pathology in animal models of Alzheimer's disease. Here, we used focused ultrasound to open the blood-brain barrier in five patients with early to moderate Alzheimer's disease in a phase I safety trial. In all patients, the blood-brain barrier within the target volume was safely, reversibly, and repeatedly opened. Opening the blood-brain barrier did not result in serious clinical or radiographic adverse events, as well as no clinically significant worsening on cognitive scores at three months compared to baseline. Beta-amyloid levels were measured before treatment using [ 18 F]-florbetaben PET to confirm amyloid deposition at the target site. Exploratory analysis suggested no group-wise changes in amyloid post-sonication. The results of this safety and feasibility study support the continued investigation of focused ultrasound as a potential novel treatment and delivery strategy for patients with Alzheimer's disease.
Discussion
We demonstrate for the first time, safe, reversible, and repeated, non-invasive opening of the BBB using MRgFUS in patients with amyloid-positive AD. BBB opening was achieved with less than 1% of the energy required to create a thermocoagulative lesion, thereby enhancing the safety and expanding the treatment envelope of the procedure30. We observed no serious clinical or radiographic adverse events, with progressively larger brain regions opened, and complete closure of the barrier within 24 h.
Editorial reading guide
- Was the evidence cross-sectional, longitudinal or experimental?
- How did the authors account for age, disease stage and differences among participants?
